Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Astellas Pharma ADR News

    9,53 $ +0,63% +0,06 $
    In : 8,8826 € | 25.04.24 21:57:52 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0YGQP
    ISIN: US04623U1025
    US-Symbol: ALPMY
    Typ: Aktie

    Astellas Pharma ADR News

    23.04.24 - PR Newswire
    Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
    Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire
    22.04.24 - PR Newswire
    Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
    Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire
    28.03.24 - PR Newswire
    China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
    China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® ...
    26.03.24 - PR Newswire
    Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
    Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire
    26.03.24 - PR Newswire
    Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
    Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer PR Newswire
    22.03.24 - PR Newswire
    Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
    Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire
    11.03.24 - PR Newswire
    FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
    FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children PR Newswire
    03.03.24 - PR Newswire
    Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
    Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan PR Newswire
    15.02.24 - PR Newswire
    Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
    Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-​Oncology Therapeutics PR Newswire
    15.02.24 - PR Newswire
    PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
    PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour ...
    06.02.24 - PR Newswire
    Astellas Makes Announcement about Management Structure
    Astellas Makes Announcement about Management Structure PR Newswire
    01.02.24 - PR Newswire
    Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
    Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl PR Newswire
    30.01.24 - PR Newswire
    Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
    Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical ...
    30.01.24 - PR Newswire
    Astellas Announces Strategic Collaboration with Mass General Brigham
    Astellas Announces Strategic Collaboration with Mass General Brigham PR Newswire
    26.01.24 - PR Newswire
    European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
    European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-​Line Treatment of Advanced ...
    08.01.24 - PR Newswire
    Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
    Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. PR Newswire
    28.12.23 - PR Newswire
    Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
    Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager PR Newswire
    21.12.23 - PR Newswire
    Astellas Completes Acquisition of Propella Therapeutics
    Astellas Completes Acquisition of Propella Therapeutics PR Newswire
    17.12.23 - PR Newswire
    EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
    EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-​Aged Children PR Newswire
    15.12.23 - PR Newswire
    PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
    PADCEV® (enfortumab vedotin-​ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer PR Newswire

    Newssuche

    Videos

    25.04.24 +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »